Potent, selective, and orally active lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors are in clinical development to determine their effects on reducing the risk of atherothrombosis and associated clinical sequelae (eg, acute coronary syndromes, ischemic stroke, etc) [1]–[4]. Here, PLA2G7 is linked to ischemic stroke.